Yup! Very few investment opportunities like RDGL. A very good risk vs reward ratio. Given the FDA guidance pathway Vivos has been on and Mayo already prepped to start clinical trials, I put IDE approval 95%+. Given the hydrogel is already proven successful on pets, human trials should go quick, 18 months, and FDA market approval is very likely.
So even at current share price, a ROI of 5x-10x is a very good bet. Much bigger ROI if holding through market approval.
$RDGL = $$$
News 
Market Data 
Discover 
